BD (Becton, Dickinson and Company) has announced a development and global distribution agreement with Check-Points for BD MAX assays that detect carbapenem-resistant organisms (CRO).
As part of the agreement, BD will distribute the Check-Direct CPE Screen for the BD MAX assay (CE IVD) outside of the US, with Check-Points maintaining exclusivity in the Netherlands. Check-Points and BD plan to develop and commercialise a next-generation CRO assay for launch outside the US in 2017.
Mindray was founded on the belief that every life is valuable. As expensive and complex technology still remains out of reach for the majority of people, we are striving to improve healthcare by developing and sharing medical technologies with the world.
B. Braun Business Centre, Sheffield
Friday 10th July 2026
BAWA Leisure
18th July 2026
Wyboston Lakes Resort
7th – 8th August 2026
Manchester (Etihad)
10th September 2026
Cavendish Conference Centre
12th September 2026
Holiday Inn, Birmingham Airport - NEC by IHG
12th October 2026
